PERIOPERATIVE MANAGEMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS

PERIOPERATIVE MANAGEMENT OF PATIENTS WITH RHEUMATOID ARTHRITIS

The paper considers the joint management of rheumatoid arthritis patients needing endoprosthetic replacement of the large joints of the lower extremities by rheumatologists and orthopedic traumatologists.Due to the fact that there are no conventional standards or guidelines for the perioperative man...

Full description

Saved in:

Bibliographic Details
Main Authors:	V. N. Amirdzhanova, M. A. Makarov, E. I. Byalik, S. A. Makarov, M. M. Lipina
Format:	Article
Language:	Russian
Published:	IMA PRESS LLC 2014-09-01
Series:	Научно-практическая ревматология
Subjects:	rheumatoid arthritis endoprosthetic joint replacement disease-modifying antirheumatic drugs genetically engineered biological agents
Online Access:	https://rsp.mediar-press.net/rsp/article/view/1956
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Biological agents for endoprosthetic joint replacement in patients with rheumatoid arthritis
by: Viktoria Nikolaevna Khlaboshina, et al.
Published: (2014-12-01)

The specific features of diagnosis of rheumatoid arthritis in real clinical practice
by: Elena Andreevna Galushko, et al.
Published: (2011-02-01)

SHOULD DISEASE-MODIFYING THERAPY BE STOPPED IN PATIENTS WITH RHEUMATOID ARTHRITIS BEFORE ENDOPROSTHETIC JOINT REPLACEMENT?
by: N. A. Savenkova, et al.
Published: (2011-06-01)

Does endoprosthetic replacement of large joints improve quality of life in patients with rheumatoid arthritis?
by: Nadezhda Alekseevna Savenkova, et al.
Published: (2011-02-01)

Reverse shoulder joint replacement in rheumatoid arthritis: medium-term results in 37 patients
by: M. A. Makarov, et al.
Published: (2018-09-01)

The tumor necrosis factor-α inhibitor golimumab in the treatment of rheumatoid arthritis
by: Natalia Vladimirovna Chichasova
Published: (2014-12-01)

STRATEGY FOR DOSE REDUCTION AND DISCONTINUATION OF BIOLOGICAL AGENTS IN RHEUMATOID ARTHRITIS REMISSION
by: M. A. Kotovskaya, et al.
Published: (2018-03-01)

MODERN VIEWS ON PATHOGENETIC THERAPY OF RHEUMATOID ARTHRITIS
by: D. G. Rekalov, et al.
Published: (2013-12-01)

The problem of laboratory monitoring in therapy with disease-modifying antirheumatic drugs and biological agents in patients with rheumatoid arthritis
by: Yu. V. Muravyev, et al.
Published: (2018-09-01)

Complications after endoprosthetic joint replacement in patients receiving genetically engineered biological agents
by: Elena Yuryevna Pogozheva, et al.
Published: (2012-06-01)

Difficult-to-treat rheumatoid arthritis in the clinical practice of a rheumatological hospital. First look
by: A. V. Gordeev, et al.
Published: (2022-05-01)

Targeted Therapy for Rheumatoid Arthritis in the New Era
by: WANG Jun, et al.
Published: (2025-01-01)

Rheumatoid arthritis: problems of treatment at the present stage
by: N. V. Chichasova
Published: (2018-12-01)

Rationales for discontinuation of disease-modifying antirheumatic drugs, biologic agents, and tofacitinib in rheumatoid arthritis
by: Yu. V. Muraviev, et al.
Published: (2018-12-01)

The clinical and pathogenetic value of Foxp3+ T regulatory cells in rheumatoid arthritis
by: A. S. Avdeeva, et al.
Published: (2016-10-01)

Experience with long-term use of certolizumab pegol (Cimzia)
by: Karine Arnoldovna Lytkina, et al.
Published: (2013-10-01)

CARDIOVASCULAR DISEASES IN RHEUMATOID ARTHRITIS: LATEST DATA
by: T. V. Popkova, et al.
Published: (2016-07-01)

Peculiarities of pharmacotherapy of patients with rheumatoid arthritis associated with interstitial lung disease
by: A. V. Gordeev, et al.
Published: (2024-02-01)

PERIPROSTHETIC INFECTION AFTER ENDOPROSTHETIC REPLACEMENT OF THE HIP JOINT IN PATIENTS WITH RHEUMATOID DISEASES
by: Vadim Petrovich Pavlov, et al.
Published: (2014-02-01)

Bioanalogues in the treatment of rheumatoid arthritis: current status of the problem
by: N. V. Chichasova, et al.
Published: (2024-12-01)

Impact of Adherence to Golimumab on Disease Flares in Rheumatoid Arthritis: Results from a Canadian Observational Study
by: Bessette L, et al.
Published: (2025-06-01)

Early rheumatoid arthritis therapy: comparative characteristic of delagil, sulphasalazine and methotrexate
by: T S Salnikova, et al.
Published: (2003-08-01)

End-stage rheumatoid arthritis: specific features of patient management
by: Nadezhda Aleksandrovna Shostak, et al.
Published: (2013-06-01)

Body composition and skeletal muscles status in patients with rheumatoid arthritis during treatment with biologic disease-modifying antirheumatic drugs
by: O. V. Dobrovolskaya, et al.
Published: (2025-02-01)

Predictors of biologic disease modifying antirheumatic drugs withdrawal due to the development of adverse events in patients with rheumatoid arthritis
by: E. N. Koltsova, et al.
Published: (2022-12-01)

Persistence of biological agents over an eight-year period in rheumatoid arthritis and spondyloarthritis patients
by: María Ángeles González-Fernández, et al.
Published: (2019-01-01)

Conventional synthetic disease-modifying antirheumatic drug use by race/ethnicity and factors associated with initiating biologics in Malaysian patients with rheumatoid arthritis
by: Suad Mohammed, et al.
Published: (2019-01-01)

COMPLEX TREATMENT OF COXARTHROSIS IN ADOLESCENTS WITH JUVENILE RHEUMATOID ARTHRITIS
by: O. A. Malakhov, et al.
Published: (2012-03-01)

THE IMPACT OF ADEQUATE PSYCHOPHARMACOTHERAPY ON THE EFFICIENCY OF TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: A. A. Abramkin, et al.
Published: (2018-05-01)

Severe rheumatoid arthritis with multiple baseline anti-inflammatory drugs intolerance
by: D. A. Kusevich, et al.
Published: (2016-12-01)

Safety of using genetic engineering biological agents in rheumatoid arthritis
by: N V Chichasova, et al.
Published: (2010-03-01)

COVID-19 and post-covid syndrome in patients with rheumatoid arthritis
by: E. S. Aronova, et al.
Published: (2023-08-01)

Dynamics of patient reported outcomes during the use various biological disease-modifying antirheumatic drugs for rheumatoid arthritis
by: A. E. Karateev, et al.
Published: (2022-09-01)

Switching biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in patients with rheumatoid arthritis
by: A. O. Bobkova, et al.
Published: (2023-07-01)

Characteristics of clinical manifestations and pharmacotherapy in patients with rheumatoid arthritis requiring switching between biologic disease-modifying antirheumatic drugs and Janus kinase inhibitors
by: A. O. Bobkova, et al.
Published: (2024-08-01)

The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patients
by: A. E. Karateev, et al.
Published: (2022-05-01)

The prevention of venous thromboembolism and the risk of postoperative complications in patients with rheumatoid arthritis and osteoarthritis after total hip arthroplasty
by: A. V. Rybnikov, et al.
Published: (2019-01-01)

Real-World Safety and Efficacy of Targeted Therapies in Rheumatoid Arthritis: A 5-Year, 5130-Case Follow-Up from FIRST Registry
by: Koshiro Sonomoto, et al.
Published: (2025-04-01)

FACTORS INFLUENCING THE EFFICIENCY OF THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS: THE ROLE OF COMORBID MENTAL AND SOMATIC DISEASES
by: A. A. Abramkin, et al.
Published: (2018-09-01)

NEW GUIDELINES FOR THE MANAGEMENT OF RHEUMATOID ARTHRITIS (EULAR, 2013): THE PLACE OF GLUCOCORTICOIDS
by: E. L. Nasonov
Published: (2016-12-01)